Table 1_Association between risk-weighted apolipoprotein B and prevalent kidney stones: a retrospective case-control study.docx

Objective<p>To investigate the association between risk-weighted apolipoprotein B (RW-apoB) levels and prevalent kidney stones.</p>Methods<p>This retrospective case-control study included 761 subjects, comprising a non-stone group (n = 522) and an incident kidney stone group confirmed strictly by non-contrast computed tomography (NCCT) (n = 239). Multivariable logistic regression models were utilized to evaluate the association between RW-apoB and prevalent kidney stones.

To address unmeasured confounding from potential lipid-lowering therapies, a sensitivity analysis was conducted by excluding individuals with comorbid hypertension and diabetes. Additionally, subgroup analyses were performed to assess the stability of this association across different clinical characteristics.</p>Results<p>Baseline analysis revealed that RW-apoB levels in the kidney stone group were significantly higher than those in the non-stone group (95.89 ± 28.80 vs. 88.52 ± 24.42, p < 0.001).